Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Sera Prognostics, Inc. (NASDAQ:SERA) saw a significant increase in short interest in March. As of March 31st, there was short interest totaling 381,493 shares, an increase of 54.2% from the March 15th total of 247,469 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 82,680 shares, the days-to-cover ratio is currently 4.6 days.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 22,639 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total value of $43,014.10. Following the transaction, the chief executive officer owned 741,287 shares of the company’s stock, valued at approximately $1,408,445.30. The trade was a 2.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 55,133 shares of company stock valued at $109,794 over the last quarter. 13.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sera Prognostics

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC bought a new stake in Sera Prognostics in the fourth quarter valued at about $31,000. Vanguard Personalized Indexing Management LLC bought a new stake in Sera Prognostics in the third quarter valued at about $38,000. Lido Advisors LLC bought a new stake in Sera Prognostics in the third quarter valued at about $68,000. Cetera Investment Advisers bought a new stake in Sera Prognostics in the fourth quarter valued at about $74,000. Finally, Birch Hill Investment Advisors LLC bought a new stake in Sera Prognostics in the third quarter valued at about $84,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Stock Up 1.9%

Shares of SERA opened at $2.18 on Thursday. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $4.09. The firm has a market capitalization of $85.33 million, a PE ratio of -3.21 and a beta of 1.05. The stock’s fifty day simple moving average is $2.18 and its 200-day simple moving average is $2.86.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. Sera Prognostics had a negative return on equity of 37.50% and a negative net margin of 39,417.29%.The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.03 million. Analysts anticipate that Sera Prognostics will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Sera Prognostics has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.